Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review)

  • Authors:
    • Izak Faiena
    • Eric A. Singer
    • Chris Pumill
    • Isaac Y. Kim
  • View Affiliations

  • Published online on: September 17, 2014     https://doi.org/10.3892/ijo.2014.2656
  • Pages: 2193-2198
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Prostate cancer (PCa) remains the second ranked cause of cancer deaths in the United States. The current standard of care for metastatic prostate cancer (mPCa) includes systemic therapies with no option for surgery. In contrast, in other malignancies such as breast and kidney cancer, cyto­reduction plays an integral role in the treatment of metastatic disease. In this framework, there are emerging data that suggest a potential oncologic benefit to cytoreduction in mPCa. The majority of the data are retrospective in nature suggesting that patients with mPCa who had prior radical prostatectomy (RP) had a better survival, as well as improved response to systemic therapy. Similarly, patients who presented with metastatic disease and received definitive local therapy (RP or radiation) had greater survival than patients who received no treatment. In order to confer maximum potential benefit, operating in the setting of mPCa must be technically feasible with acceptable morbidity. It has been demonstrated in many studies that operating on locally advanced disease (T3a/b) does have similar morbidity as lower stage cancer. This may be applicable in the metastatic setting, because although PCa may have metastasized, it may remain locally advanced. On the molecular level there are a number of explanations concerning the potential benefit of cytoreduction. However, these ideas remain specul­ative with no concrete evidence to date.
View References

Related Articles

Journal Cover

December-2014
Volume 45 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Faiena I, Singer EA, Pumill C and Kim IY: Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review). Int J Oncol 45: 2193-2198, 2014.
APA
Faiena, I., Singer, E.A., Pumill, C., & Kim, I.Y. (2014). Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review). International Journal of Oncology, 45, 2193-2198. https://doi.org/10.3892/ijo.2014.2656
MLA
Faiena, I., Singer, E. A., Pumill, C., Kim, I. Y."Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review)". International Journal of Oncology 45.6 (2014): 2193-2198.
Chicago
Faiena, I., Singer, E. A., Pumill, C., Kim, I. Y."Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review)". International Journal of Oncology 45, no. 6 (2014): 2193-2198. https://doi.org/10.3892/ijo.2014.2656